Skip to main content
7 search results for:

Midostaurin 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 04-07-2017 | Acute myeloid leukemia | News | Article

    Midostaurin prolongs survival in FLT3-mutated AML

    Adding the multitargeted kinase inhibitor midostaurin to standard chemotherapy prolongs survival among patients with acute myeloid leukemia and ​​​​​​​an fms-related tyrosine kinase 3 mutation, study findings indicate.

  2. 03-05-2017 | Regorafenib | Drug approval | Article
    approvalsWatch

    Regorafenib approved for liver cancer, midostaurin for AML

    The LeukoStrat CDx FLT3 Mutation assay has been approved as a companion diagnostic for midostaurin in AML patients.

  3. 25-08-2017 | Leukemia | Article

    Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial

    This long-term follow-up of this phase II trial of the oral multikinase inhibitor midostaurin demonstrates its durable activity and tolerability in advanced systemic mastocytosis patients. Leukemia 2017. doi:10.1038/leu.2017.234

  4. 17-08-2017 | EMA | Drug approval | Article
    approvalsWatch

    Multiple orphan medications get nod from EMA

    By Shreeya Nanda m edwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group See also: OS promise for 177Lu-dotatate in neuroendocrine tumors Avelumab given accelerated approval for metastatic Merkel cell carcinoma Midostaurin prolongs survival in FLT3-mutated AML Regorafenib approved for liver cancer, midostaurin for AML

  5. 14-03-2017 | Leukemia | Editorial | Article

    FMS-like tyrosine kinase 3 (FLT3)-inhibition in FLT3 mutated acute myeloid leukemia: A promising approach

    The first results with midostaurin suggested further investigation of midostaurin in combination with other agents [17].

  6. 07-07-2017 | Acute myeloid leukemia | News | Article

    Selective FLT3 inhibition promising in relapsed, refractory AML

    . © 2017 Springer Healthcare part of the Springer Nature group See also: Midostaurin prolongs survival in FLT3-mutated AML

  7. 01-12-2015 | Hematologic cancers | Article

    Molecular therapy for acute myeloid leukaemia

    Addition of targeted agents A series of small-molecule FLT3 tyrosine kinase inhibitors (TKIs) have been developed and tested in patients with AML, including midostaurin, lestaurtinib, lefitinib, sorafenib, quizartinib, and crenolanib.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.